Myelodysplastic Syndrome – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Myelodysplastic Syndrome – Pipeline Review, H1 2020’, provides an overview of the Myelodysplastic Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome

– The report reviews pipeline therapeutics for Myelodysplastic Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Myelodysplastic Syndrome therapeutics and enlists all their major and minor projects

– The report assesses Myelodysplastic Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

A. Menarini Industrie Farmaceutiche Riunite Srl

AbbVie Inc

Acceleron Pharma Inc

Acrotech Biopharma LLC

Actinium Pharmaceuticals Inc

Aeglea BioTherapeutics Inc

Agios Pharmaceuticals Inc

AIMM Therapeutics BV

ALX Oncology Inc

Amphivena Therapeutics Inc

Angiocrine Bioscience Inc

Anhui Anke Biotechnology (Group) Co Ltd

Apogenix AG

Aprea Therapeutics AB

AptaBio Therapeutics Inc

Aptevo Therapeutics Inc

Aptose Biosciences Inc

Argenx SE

Ascentage Pharma Group International

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Aurigene Discovery Technologies Ltd

Bayer AG

Bellicum Pharmaceuticals Inc

BerGenBio ASA

Bio-Path Holdings Inc

BioLineRx Ltd

BioMed Valley Discoveries Inc

BioTheryX Inc

Boehringer Ingelheim International GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Calithera Biosciences Inc

CellCentric Ltd

Cellenkos Inc

Cellerant Therapeutics Inc

Celularity Inc

Celyad Oncology

CheckPoint Immunology Inc

Chimerix Inc

China NT Pharma Group Co Ltd

Chordia Therapeutics Inc

Cleave Therapeutics Inc

Constellation Pharmaceuticals Inc

CrystalGenomics Inc

Cyclacel Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

DC Prime BV

Deciphera Pharmaceuticals Inc

Denovo Biopharma LLC

DiNonA Inc

Elixirgen Therapeutics LLC

ExCellThera Inc

Fate Therapeutics Inc

Forma Therapeutics Inc

Fujifilm Holdings Corp

Gadeta BV

Gamida Cell Ltd

Geron Corp

Gilead Sciences Inc

GlaxoSmithKline Plc

GlycoMimetics Inc

GT Biopharma Inc

H3 Biomedicine Inc

Harrow Health Inc

Helocyte Biosciences Inc

HemoGenyx LLC

Hutchison MediPharma Ltd

I-Mab Biopharma Co Ltd

iCell Gene Therapeutics LLC

IGF Oncology LLC

Imago BioSciences Inc

Immune System Key Ltd

ImmunityBio Inc

ImmunoGen Inc

Incysus Therapeutics Inc

Incyte Corp

Inmune Bio Inc

Io Therapeutics Inc

Jasper Therapeutics Inc

Jazz Pharmaceuticals Plc

Johnson & Johnson

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Keros Therapeutics Inc

Kiadis Pharma NV

Les Laboratoires Servier SAS

Lixte Biotechnology Holdings Inc

MacroGenics Inc

Magenta Therapeutics Inc

Mana Therapeutics Inc

Marker Therapeutics Inc

Mateon Therapeutics Inc

MediGene AG

Medivir AB

MedPacto Inc

MEI Pharma Inc

Merck & Co Inc

Merus NV

Millennium Pharmaceuticals Inc

Molecular Templates Inc

Mustang Bio Inc

Nanjing Legend Biotech Co Ltd

NantKwest Inc

Nemucore Medical Innovations Inc

Newave Pharmaceutical Inc

NexImmune Inc

Nkarta Inc

Nohla Therapeutics Inc

Novartis AG

Oncoceutics Inc

Oncoheroes Biosciences Inc

Onconova Therapeutics Inc

Oncotelic Inc

OncoTherapy Science Inc

Ono Pharmaceutical Co Ltd

Opsona Therapeutics Ltd

Orca Biosystems Inc

Orsenix Holdings BV

Oxstem Ltd

PersImmune Inc

Pfizer Inc

Pharma Mar SA

Pinotbio Inc

Plexxikon Inc

Prelude Therapeutics Inc

PRISM Pharma Co Ltd

Rafael Pharmaceuticals Inc

Ryvu Therapeutics SA

Sanofi

Seattle Genetics Inc

Sensei Biotherapeutics Inc

Shanghai Yingli Pharmaceutical Co Ltd

Silence Therapeutics Plc

Sino Biopharmaceutical Ltd

SiNOPSEE Therapeutics Pte Ltd

SpecificiT Pharma Inc

Stelexis Therapeutics LLC

Sumitomo Dainippon Pharma Co Ltd

Surface Oncology Inc

Syntrix Biosystems Inc

Tacitus Therapeutics Inc

Takara Bio Inc

Teva Pharmaceutical Industries Ltd

TheraPharm Deutschland GmbH

Toko Pharmaceutical Industries Co Ltd

Tolero Pharmaceuticals Inc

TOT Biopharm Co Ltd

Treadwell Therapeutics Inc

Trethera Corp

Trillium Therapeutics Inc

Vyriad Inc

Y-Biologics Inc

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Introduction

Myelodysplastic Syndrome - Overview

Myelodysplastic Syndrome - Therapeutics Development

Myelodysplastic Syndrome - Therapeutics Assessment

Myelodysplastic Syndrome - Companies Involved in Therapeutics Development

Myelodysplastic Syndrome - Drug Profiles

Myelodysplastic Syndrome - Dormant Projects

Myelodysplastic Syndrome - Discontinued Products

Myelodysplastic Syndrome - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Myelodysplastic Syndrome, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Myelodysplastic Syndrome – Pipeline by 4SC AG, H1 2020

Myelodysplastic Syndrome – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020

Myelodysplastic Syndrome – Pipeline by AbbVie Inc, H1 2020

Myelodysplastic Syndrome – Pipeline by Acceleron Pharma Inc, H1 2020

Myelodysplastic Syndrome – Pipeline by Acrotech Biopharma LLC, H1 2020

Myelodysplastic Syndrome – Pipeline by Actinium Pharmaceuticals Inc, H1 2020

Myelodysplastic Syndrome – Pipeline by Aeglea BioTherapeutics Inc, H1 2020

Myelodysplastic Syndrome – Pipeline by Agios Pharmaceuticals Inc, H1 2020

Myelodysplastic Syndrome – Pipeline by AIMM Therapeutics BV, H1 2020

Myelodysplastic Syndrome – Pipeline by ALX Oncology Inc, H1 2020

Myelodysplastic Syndrome – Pipeline by Amphivena Therapeutics Inc, H1 2020

Myelodysplastic Syndrome – Pipeline by Angiocrine Bioscience Inc, H1 2020

Myelodysplastic Syndrome – Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H1 2020

Myelodysplastic Syndrome – Pipeline by Apogenix AG, H1 2020

Myelodysplastic Syndrome – Pipeline by Aprea Therapeutics AB, H1 2020

Myelodysplastic Syndrome – Pipeline by AptaBio Therapeutics Inc, H1 2020

Myelodysplastic Syndrome – Pipeline by Aptevo Therapeutics Inc, H1 2020

Myelodysplastic Syndrome – Pipeline by Aptose Biosciences Inc, H1 2020

Myelodysplastic Syndrome – Pipeline by Y-Biologics Inc, H1 2020

Myelodysplastic Syndrome – Pipeline by ZIOPHARM Oncology Inc, H1 2020

Myelodysplastic Syndrome – Dormant Projects, H1 2020

Myelodysplastic Syndrome – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Myelodysplastic Syndrome, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports